Clinical Trial Update: DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension [Phase 3]

View source ↗

Summary

A long-term safety extension study (DORADO-AC-EX, DAR-312) of darusentan in resistant hypertension has been terminated, providing an update on the Phase 3 DORAD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Resistant Hypertension

Drugs mentioned

• Darusentan (darusentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Hypertension | Phase 3 | Status: TERMINATED